Abstract:Alexander Keenan, 1 Hoa H Le, 1 Kavita Gandhi, 2 Lola Adedokun, 3 Eddie Jones, 4 Mia Unsworth, 4 James Pike, 5 Emily Trenholm 4 1 Scientific Affairs, Janssen Pharmaceuticals Inc., Titusville, NJ, USA; 2 Research and Development, Janssen Pharmaceuticals Inc., Titusville, NJ, USA; 3 Research and Development, Janssen-Cilag Ltd, High Wycombe, UK; 4 Central Nervous System, Adelphi Real World, Bollington, Cheshire, UK; 5 Statistics & Data Analytics, Adelphi Real World, Bollington, Cheshire, UK Correspondence: Mia Unsworth, Adelphi Real World, Adelphi Mill, Grimshaw Lane, Macclesfield, Bollington, Cheshire, SK10 5JB, United Kingdom, Tel +441625578677, Email Introduction: Multiple sclerosis (MS) is a neurodegenerative disease characterized by progressive deterioration of cognitive and physical functioning, reducing activities of daily living and quality of life (QoL). Several treatments are available that modify the course of the disease and reduce the frequency of relapses. Although effective, all treatment options are accompanied by adverse events, and this study aimed to assess the extent to which patients were involved in the choice of treatment. Methods: Data were drawn from the Adelphi Multiple Sclerosis Disease Specific Program (DSP)TM, a cross-sectional survey of healthcare practitioners (HCP) and their patients with MS in real-world clinical settings in Europe and the United States (US) between December 2020 and July 2021. HCPs reported patient demographics, clinical characteristics, current and previous treatment, and treatment outcomes. Patients voluntarily completed questionnaires reporting the physical and psychological impact of their MS and its treatment. Regression analysis with inverse probability of treatment weighting was used to compare treatment outcomes in patients actively involved in their current treatment choice with those who were not. Results: Of a total of 692 patients, median age 40 years and 64% female, mostly diagnosed with relapsing-remitting MS, those who were involved in shared decision-making tended to choose oral therapies such as dimethyl fumarate more often than HCPs. MS had greater impact on physical and psychological functioning in patients whose HCP made treatment decisions solely. Patients involved in decision-making reported greater satisfaction with their treatment and a better QoL. Discussion: Because no single optimal therapy exists for patients with MS, treatments should be individualized with consideration of patients' preferences. Our study shows that shared decision-making is under-utilized in the management of MS and supports the benefits of patient involvement. Conclusion: Patients who have an active role in treatment decision-making show improved wellbeing and QoL, and overall treatment satisfaction. Plain Language Summary: Multiple sclerosis (MS) is a disease that affects the brain, causing symptoms such as blurred vision and problems with movements, thoughts, and feelings. MS is a lifelong condition that becomes worse over time and limits the activities that people can do. There are many treatments that can help to reduce relapses (when symptoms become worse), but all have their benefits and drawbacks. It is often the physician who decides which treatment to use, but we wanted to know if patients would feel better if they were involved in the decision. Using our standardized and validated questionnaires, we surveyed physicians and nurses who treat patients with MS in Europe and the United States of America between December 2020 and July 2021, to assess how they felt about the treatment they chose and its effect on the patient. We also asked the patients themselves how they felt about their illness and treatment, whether they were given the chance to choose which treatment to take, and how their treatment affected their symptoms and overall quality of life. The information provided by both the physicians and their patients was used to compare how patients responded when they were involved in the treatment decisions. We found that patients who were involved in choosing their treatment were more satisfied with their treatment and responded better than those whose physicians decided alone. Therefore, it is important for physicians treating patients with MS to consider their patients' preferences when deciding which treatment is best for them. Keywords: multiple sclerosis, patient preference, decision-making, shared, multinational, survey Multiple sclerosis (MS) is a demyelinating disease of the central nervous system with a variable clinical course characterized by neurological dysfunction and -Abstract Truncated-

The state of multiple sclerosis: current insight into the patient/health care provider relationship, treatment challenges, and satisfaction

Shared Decision-Making in the Treatment of Multiple Sclerosis: Results of a Cross-Sectional, Real-World Survey in Europe and the United States

Approach to Managing the Initial Presentation of Multiple Sclerosis: A Worldwide Practice Survey

Patient and Physician Perspectives of Treatment Burden in Multiple Sclerosis

Multiple Sclerosis Multidisciplinary Care: a national survey and lessons for the global community

The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across Europe

Preferences, Adherence, and Satisfaction: Three Years of Treatment Experiences of People with Multiple Sclerosis

Clinical management of multiple sclerosis: the treatment paradigm and issues of patient management

Information and Resources Important to the Quality of Life of People Living with Multiple Sclerosis

An exploratory study regarding communication facilitators and barriers reported by a cohort of multiple sclerosis (MS) community members from the international massive open online course 'Understanding MS'

Impact on interpersonal relationships among patients with multiple sclerosis and their partners

Insights for Healthcare Providers on Shared Decision-Making in Multiple Sclerosis: A Narrative Review

Multiple Sclerosis: Systemic Challenges to Cost-Effective Care

Comprehensive Approach to Management of Multiple Sclerosis: Addressing Invisible Symptoms—A Narrative Review

Multiple sclerosis diagnosis: Knowledge gaps and opportunities for educational intervention in neurologists in the United States

Exploring the relationship between neurologists and older persons with multiple sclerosis through the lens of social support theory

Patient's point of view on the use of telemedicine in multiple sclerosis: a web-based survey

Patients and Partners in Research: Patient and Caregiver Perceptions of Research Engagement and the Role of Their Psychosocial States in Participation

Access to Care and Health-Related Quality of Life in Multiple Sclerosis

Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

'So Let's Go On Like This?'—Shared Decision‐Making and the Use of Outcome Information in Routine Care Management for People With Multiple Sclerosis